Research output per year
Research output per year
MSc(Hannover), PhD(Zurich), Habiliation (E.T.H.Zurich)
BS8 1TD
Current work in the Berger-Schaffitzel lab focuses on the ribosome, translational control mechanisms, in particular nonsense-mediated mRNA decay (NMD), and ribosome display.
Nonsense-mediated mRNA decay (NMD)
Nonsense-mediated mRNA decay (NMD) represents a key surveillance mechanism to quality control the expression of normal and aberrant mRNAs in eukaryotes. NMD recognizes and degrades transcripts with premature termination codons (PTCs). These can be introduced into the mRNA by mutations, transcriptional errors, and aberrant splicing, but are also present in 5-20% of normal transcripts. By degrading PTC-containing mRNAs, NMD limits the production of potentially harmful, C-terminally truncated proteins. NMD thus represents one of the main quality control mechanisms of the eukaryotic cell. In addition, NMD is an important regulator of overall eukaryotic gene expression.
Translation is a prerequisite for the recognition of a PTC-containing mRNA. Despite years of intense research, the molecular mechanisms which allows discriminating a PTC from a normal termination codon, the key step in NMD, remains poorly understood. A set of conserved NMD effectors has been identified: the UP-Frameshift factors UPF1, UPF2, and UPF3B and the SMG proteins. Our team studies the function and structure of these NMD factors using biochemistry, biophysics and structural biology, supported by a Wellcome Trust Investigator award, a Marie Sklodowska-Curie Fellowship to Mirella Vivoli-Vega, (CSC) and SWBio DTP scholarships.
Selected recent publications:
Ribosome Display and Novel Snakebite Therapy Platforms
The first-choice treatment of snakebite envenoming is antivenom, and yet this Neglected Tropical Disease still, annually, causes up to 138,000 deaths and 400,000 disabilities in surviving victims. Current anti-venoms (AVs) are based on antibodies from hyperimmunised horses and sheep and are weakly effective. This approach has many additional disadvantages, in particular it cannot rationally incorporate the distinct immunogenicity or toxicity of the venoms’ proteins into the design - venoms comprise between 20 to >100 proteins that vary in molecular mass, bioactivity and pathogenicity.
We work on an innovative solution to change snakebite treatment in two international consortia funded by the EC and the Wellcome Trust. We rationally design nanobodies and ADDobodies/ ADDomers (ADDovenom, https://addovenom.com) to bind and neutralise the pathogenic function of all toxins of the medically most important snakes in Sub-Saharan Africa, and without adverse effect risk. We will achieve this by applying cutting-edge mass spectroscopy techniques to snake venoms to enable informed target choices, by protein engineering, by ribosome display in vitro selection technology and high-throughput protein production methods.
Selected publications:
Free Fatty Acid Binding to SARS-CoV-2 Spike protein
We discovered a novel Free Fatty Acid (FFA)-binding pocket in SARS-CoV-2 Spike (S) glycoprotein, with low nanomolar affinity for linoleic acid (LA), an essential FFA with key roles in lipid metabolism and inflammation modulation. Intriguingly, we found that LA binding is highly conserved in severely pathogenic human CoVs SARS-CoV, MERS-CoV, SARS-CoV-2 and all Variants of Concern (VOCs) including omicron. In marked contrast, endemic human CoVs causing only mild disease (common cold) do not appear to have a functional LA-binding pocket. We determined that LA treatment inhibits viral infectivity outside of cells, and viral replication inside of cells, revealing two modes of action that hold promise for potential future FFA-based treatments.
Selected Publications:
In all our projects, we rely on biochemical methods, state-of-the-art protein production and in vitro translation systems. We use biophysics to study multi-protein complexes and structural biology, crystallography and cryo-EM. We have established a Wellcome Trust-funded GW4 Facility for high-resolution Cryo-EM with a 200kV Talos Arctica with energy filter and K2 Direct Electron Detector http://www.bristol.ac.uk/wolfson-bioimaging/equipment/cryo-em/. Image processing is supported by a BBSRC-funded BlueCryo high-performance computing cluster.
Research output: Contribution to journal › Article (Academic Journal) › peer-review
Research output: Contribution to journal › Article (Academic Journal) › peer-review
Research output: Contribution to journal › Article (Academic Journal) › peer-review
Berger-Schaffitzel, C. H. (Principal Investigator)
1/10/24 → 30/09/27
Project: Research, Parent
Berger-Schaffitzel, C. H. (Principal Investigator)
1/10/24 → 30/09/27
Project: Research
Berger-Schaffitzel, C. H. (Principal Investigator)
1/09/24 → 31/08/26
Project: Research
Buchanan, C. (Creator), Gaunt, B. (Creator), Harrison, P. (Creator), Yang, Y. (Creator), Liu, J. (Creator), Khan, A. (Creator), Giltrap, A. (Creator), Le Bas, A. (Creator), Ward, P. (Creator), Gupta, K. (Creator), Dumoux, M. (Creator), Daga, S. (Creator), Picchiotti, N. (Creator), Baldassarri, M. (Creator), Benetti, E. (Creator), Fallerini, C. (Creator), Fava, F. (Creator), Giliberti, A. (Creator), Koukos, P. (Creator), Lakshminarayanan, A. (Creator), Xue, X. (Creator), Papadakis, G. (Creator), Deimel, L. (Creator), Casablancas-Antras, V. (Creator), Claridge, T. (Creator), Bonvin, A. (Creator), Sattentau, Q. (Creator), Furini, S. (Creator), Gori, M. (Creator), Huo, J. (Creator), Owens, R. (Creator), Schaffitzel, C. (Creator), Berger, I. (Creator), Renieri, A. (Creator), Naismith, J. (Creator), Baldwin, A. (Creator) & Davis, B. (Creator), Zenodo, 26 Feb 2022
DOI: 10.5281/zenodo.6299883, https://zenodo.org/record/6299883
Dataset